Merrimack Pharmaceuticals’ stock plunged more than 32 percent after the company announced the termination of the SHERLOC Phase II clinical trial.
The U.S. Food and Drug Administration rejected Novartis’ bid to repurpose canakinumab, a drug already approved for rare inflammatory diseases, for use in a group of heart attack survivors.
Merck & Co.’s cancer drug Keytruda in combination with Pfizer Inc.’s Inlyta met the main goals of a late-stage study for the most common form of kidney cancer.
The U.S. Food and Drug Administration approved Pfizer Inc.’s Talzenna (talazoparib) for an advanced form of breast cancer.
Watertown, Mass.-based SQZ Biotechnologies could be on the receiving end of up to $1 billion following the company’s signing of an expansion agreement with pharma giant Roche.
Bristol-Myers Squibb and Israel’s Compugen will collaborate in clinical trials for patients with advanced solid tumors.
An advisory panel to the U.S. Food and Drug Administration voted unanimously in favor of Celltrion Pharm Inc.’s copycat drug of Roche Holding AG’s blood cancer drug Rituxan.
Affimed N.V. put on hold the testing of the drug developer’s experimental cancer drug following the death of a patient and two life-threatening events.
According to a drug shortage list provided by the U.S. Food and Drug Administration, there have been more than 100 drugs that have faced shortages during 2018.
Seattle Genetics and development partner Takeda Pharmaceutical announced stellar Phase III data from the ECHELON-2 clinical trial of Adcetris (brentuximab vedotin) for peripheral T-cell lymphoma.
Backed by GlaxoSmithKline and Boston’s SV Health Investors, a new biopharmaceutical company known as Sitryx launched with $30 million in a Series A funding round.
Medopad, a U.K.-based medical firm, and China-based Tencent Holdings have teamed up on a project that will attempt to harness artificial intelligence in the diagnosis of Parkinson’s disease.
Immunotherapy – reprogramming the immune system to attack cancer cells – is a rapidly growing and promising field in cancer research and treatment.
German company Bayer AG is laying off 227 staffers at the company’s manufacturing plant in Berkeley, California. Most of the cuts took place on October 3, 2018.
A single leukemia cell inadvertently got mixed in with a batch of a patient’s immune cells that were being manufactured into a CAR-T cell therapy and it acquired resistance to the treatment with deadly results, University of Pennsylvania researchers reported.
Waltham, Mass.-based Dragonfly Therapeutics struck a licensing agreement worth up to $695 million with Merck, which will license exclusive rights to Dragonfly’s TriNKET technology platform for a number of solid-tumor programs.
Sanofi SA’s skin cancer drug Libtayo, made in partnership with Regeneron Pharmaceuticals Inc., was approved by the U.S. Food and Drug Administration.
Switzerland’s Roche is buying UK-based Tusk Therapeutics in a deal that could hit EUR 655 million.
Pfizer Inc.’s once-daily oral drug Vizimpro to treat a rare form of lung cancer received approval from the U.S. Food and Drug Administration.
Chinese manufacturer Cellular Biomedicine has been enlisted to make Novartis’ $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world’s most populous country.